Intended for healthcare professionals

News

Ketamine based drug should be available for treatment resistant depression, says FDA panel

BMJ 2019; 364 doi: https://doi.org/10.1136/bmj.l858 (Published 22 February 2019) Cite this as: BMJ 2019;364:l858